Structure-Based Discovery of a Highly Selective, Oral Polo-Like Kinase 1 Inhibitor with Potent Antileukemic Activity
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Jianyu Nie und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Polo-Like Kinase 1, Proto-Oncogene Proteins, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Anhui Province.
Abstract (Originalsprache)
Polo-like kinase 1 (PLK1) plays pivotal roles in cell division and cancer pathogenesis, making it a highly coveted therapeutic target for anticancer strategies. This article reports a series of PLK1 inhibitors developed using a structure-based strategy, culminating in the discovery of compound B31, a novel isoform-specific PLK1 inhibitor with excellent kinome selectivity. In vitro, this compound exhibited superior anticancer potency across a broad spectrum of cell lines, particularly against K562, achieving a remarkable IC50 value of 0.08 nM. In a mouse model harboring subcutaneous K562 tumors, oral administration of B31 at dosages of 10 or 20 mg/kg twice weekly exhibited remarkable antileukemic activity. B31 had minimal impact on HEK293T cells and very weak inhibitory activity against the hERG channel. Furthermore, in the acute toxicity test, this compound demonstrated an extraordinary safety profile even at a dosage of 500 mg/kg, highlighting its potential as a novel antileukemic agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, China.
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
- Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
ORCID-Profile: Zhenming Liu, Zhongtang Li, Chenzhong Liao
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province
- Anhui Provincial Key Research and Development Plan
Zitieren
APA
Nie, J., Sun, X., He, Y., Zhu, M., Zhang, X., Wang, Q., Liu, Z., Xie, Z., Li, Z., & Liao, C. (2025). Structure-Based Discovery of a Highly Selective, Oral Polo-Like Kinase 1 Inhibitor with Potent Antileukemic Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02422
Vancouver
Nie J, Sun X, He Y, Zhu M, Zhang X, Wang Q, et al. Structure-Based Discovery of a Highly Selective, Oral Polo-Like Kinase 1 Inhibitor with Potent Antileukemic Activity. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02422
BibTeX
@article{Nie2025,
author = {Nie, Jianyu and Sun, Xiaojiao and He, Yan and Zhu, Mingxin and Zhang, Xinglong and Wang, Qin and Liu, Zhenming and Xie, Zhouling and Li, Zhongtang and Liao, Chenzhong},
title = {Structure-Based Discovery of a Highly Selective, Oral Polo-Like Kinase 1 Inhibitor with Potent Antileukemic Activity},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02422}
}
EUVIMED